ProPhase Labs Inc (PRPH)

ProPhase Labs Inc. is a healthcare company listed on OTC Markets under the ticker PRPH. The company operates as a common equity security and focuses on developing and commercializing novel drugs, dietary supplements, and related compounds in the United States. Its business is organized into two segments: Diagnostic Services and Consumer Products.

Within consumer products, ProPhase Labs markets TK-branded dietary supplements, including Legendz XL for male sexual enhancement and Triple Edge XL for energy and stamina support. In diagnostics, the company provides COVID-19-related clinical testing services, such as PCR tests for COVID-19 and Influenza A and B, along with rapid antigen testing. It also works on genomic testing technologies, the BE-Smart Esophageal Pre-Cancer screening test, and product candidates including LB-1 and LB-2 for potential applications in cancer, inflammatory diseases, and memory-related conditions. Founded in 1989 and headquartered in Garden City, New York, the company was previously known as The Quigley Corporation.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-PRPH
$0.019
55.0% Upside
Bargain
Not available
Not available
Weak
0.0%
November 13, 2026
0.1x
191.008 K
9.334 M
97.5%
97.9%
-4.8
24.7%
Valuation • Fair Value

ProPhase Labs Inc (OTC-PRPH) Fair Value by Valuation Model

Review the available estimates for ProPhase Labs Inc (OTC-PRPH), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.019

Estimated upside of 55.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.019

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for ProPhase Labs Inc (OTC-PRPH) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for ProPhase Labs Inc (OTC-PRPH)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

3.847 M

Current operating scale indicator.

Revenue Forecast

41.69 M

Forward revenue estimate.

EBITDA

-11.635 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review ProPhase Labs Inc (OTC-PRPH) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for ProPhase Labs Inc (OTC-PRPH)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-4.13

No elevated caution signal from this screen.

Altman Z-Score

-4.8

Lower score that deserves closer risk review.

FCF / Net Income

24.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for ProPhase Labs Inc (OTC-PRPH). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for ProPhase Labs Inc (OTC-PRPH)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

56

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for ProPhase Labs Inc (OTC-PRPH), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for ProPhase Labs Inc (OTC-PRPH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for ProPhase Labs Inc (OTC-PRPH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for ProPhase Labs Inc (OTC-PRPH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for ProPhase Labs Inc (OTC-PRPH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for ProPhase Labs Inc (OTC-PRPH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ Fast Investor Answers

ProPhase Labs Inc (OTC-PRPH) Stock FAQ

Data-supported answers about ProPhase Labs Inc (OTC-PRPH), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.019
Estimated upside 55.0%
Valuation Rating
Undervalued
Estimated upside of 55.0%
Financial Health
Weak
Current financial-health read

The current fair value estimate for ProPhase Labs Inc (OTC-PRPH) is $0.019. This implies an estimated upside of 55.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 55.0% versus the current market price.

The current financial health read for ProPhase Labs Inc (OTC-PRPH) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for ProPhase Labs Inc (OTC-PRPH) is November 13, 2026.

The latest available data indicates no current dividend yield for ProPhase Labs Inc (OTC-PRPH).

The current market capitalization listed for ProPhase Labs Inc is 191.008 K.

The current enterprise value listed for ProPhase Labs Inc is 9.334 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for ProPhase Labs Inc is OTC-PRPH, and the stock is listed on OTC Markets.

ProPhase Labs Inc (OTC-PRPH) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for ProPhase Labs Inc is 97.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for ProPhase Labs Inc is 97.9%. Free float helps investors understand how much of the share base is available for public trading.